全福生技和生技中心共同合辦之研討會 (12/16)

November 19th, 2015 | Categories: 2015, 其他廣宣 | Tags:

Dengue Diseases: from Epidemiology to Treatment

 
登革熱被世界衛生組織(WHO)列為最重要的蚊媒病毒疾病。由於病毒載體在全球之散佈,疾病持續快速擴散中。近年來,全球暖化及洲際飛航更為登革熱的傳播推波助瀾,由熱帶及亞熱帶向各國蔓延。今年台灣亦飽受登革熱肆虐,入夏以來全台累積病例破30,000例,值得各界關心。
 
防治登革熱需多管齊下,公衛、醫療及環境並重。在醫療方面尚有極大的未滿足需求,有鑑於此,全福生物科技公司、生物技術開發中心及生技醫藥國家型科技計畫訂於20151216日舉辦”Dengue Diseases: from Epidemiology to Treatment”研討會,邀請國際級學者及國內專家分享心得,期能加深各界對登革熱的認知和注意,並對全球研發之最新趨勢更為了解。
 
大會由參與登革熱疫情控制的蘇益仁醫師開場,分享其身居第一線的防疫及治療策略。麻省理工學院Steven R. Tannenbaum教授多年來為人類面臨的重大問題找尋創新的解決方案,遠道而來分享登革熱預後相關之生物標記研究。另外,還邀請多位在研究上卓具經驗的國內外專家,分別就登革熱於亞太地區的發展、診斷方法、小分子、單株抗體、及疫苗各方面的藥物開發議題進行探討。希望藉此機會,讓大家對登革熱的流病學及防治發展有進一步的了解認識,並期許在各界的持續努力下,能有效達成緩解傳染病威脅的目標。
 


 

活動名稱:Dengue Diseases: from Epidemiology to Treatment
時間:20151216 (週三上午9時至下午5
地點:中央研究院人文社會科學館第二會議室 (2nd Conference Room, Research Center for Humanities and Social Sciences, Academia Sinica, Taipei, Taiwan) 點我看地圖 (位置24)
主辦單位:全福生物科技股份有限公司、財團法人生物技術開發中心
協辦單位:生技醫藥國家型科技計畫
使用語言:全程以英文進行
報名方式:>>>線上報名 (本次研討會不收費,但需先報名以利於統計人數,報名後敬請準時出席)
聯絡人: 全福生技  李元銘 (ym.lee@brimbiotech.com, 02-2659-8586 ext. 109)
              生技中心  孫亦俊 (ericsun@dcb.org.tw, 02-2655-8233 ext.7405)

 

Time

Topic

Speaker

08:50 – 09:20

Registration

09:20 – 09:25

Opening remarks

Lawrence Gan, Ph.D.,

President & CEO, DCB, Taiwan

09:25 – 10:00

Keynote:

Dengue Infection, Control, and Therapy in Taiwan

Moderator: Chin-Hui Yang, M.D., Ph.D.,

Director, Division of Acute Infectious Diseases, Taiwan CDC

Ih-Jen Su, M.D., Ph.D.,

Distinguished Professor, Southern Taiwan University of Science and Technology, Taiwan

10:00 – 10:35

Ideal dengue solution for populations at risk

Moderator: Hong-Jen Chang M.D., M.P.H.,

Vice President, Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA)

Jason Huang, M.D., J.D.,

Regional Therapeutic Area of Infectious Disease, Vaccine and Immunology, J & J

10:35 – 10:50

Break

10:50 – 11:25

Time dependence of biomarkers in febrile and defervescence stages of DF and their importance in predicting DHF

Moderator: Lawrence Gan Ph.D.,

President & CEO, DCB, Taiwan

Steven R. Tannenbaum, Ph.D.,

Professor, MIT, USA

11:25 – 12:10

CLEC5A as therapeutic target for flaviviral infections

Moderator: Haishan Jang Ph.D.,

CEO, BRIM Biotechnology, Taiwan

Shie-Liang Hsieh, Ph.D.,

Distinguished Research Fellow, Academia Sinica, Taiwan

12:10 – 13:30

Lunch

13:30 – 13:40

Afternoon Section Introduction: Haishan Jang, Ph.D., CEO, BRIM Biotechnology, Taiwan

Moderator: Lilly Zhang, M.S., MBA, Senior Director, BRIM Biotechnology, Taiwan

13:40 – 14:15

Drug repurposing for dengue

Yi-Ling Lin, Ph.D.,

Research Fellow and Deputy Director, Academia Sinica, Taiwan

14:15 – 14:50

VIS513: A designer immunotherapy for dengue fever

Zach Shriver, Ph.D.,

Vice President of Research, Visterra Therapeutics, USA

14:50 – 15:10

Break

15:10 – 15:45

The development of antibody therapy and vaccine targeting DENV NS1

Yee-Shin Lin, Ph.D.,

Distinguished Professor, NCKU, Taiwan

15:45 – 16:20

Lipidated vaccines against dengue virus infection

Hsin-Wei Chen, Ph.D.,

Associate Investigator, NHRI, Taiwan

16:20 – 16:55

Anti-dengue virus drug discovery at NHRI

Andrew Yueh Yueh, Ph.D.,

Associate Investigator, NHRI, Taiwan

16:55 – 17:00

Closing Remarks

Frank W Lee, Ph.D.,

Founder, BRIM Biotechnology, Taiwan

※主辦單位保留活動變更權利

 

|

Referrer Plugin made by Electric Guitars.